🎁 Code: '500freebie' - Spend $500, add an item from Other Peptides, get it for free (exclusions apply)
🚚 Free Shipping when you spend $350 or more
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically designed to extend the half-life of the naturally occurring hormone and enhance its effects on growth hormone (GH) secretion. In recent years, there has been a growing interest in peptide-based therapies due to their potential to influence various physiological processes, particularly those related to muscle growth, recovery, and overall anabolic support. CJC-1295 has emerged as a prominent tool in this field, known for its ability to sustain elevated GH levels and promote anabolic processes essential for muscle development. This article explores the mechanism of action of CJC-1295, examines relevant clinical studies and its potential in promoting muscle growth and recovery.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), specifically designed to increase the half-life of the peptide and enhance its therapeutic potential in stimulating growth hormone (GH) release. The structure of CJC-1295 incorporates modifications that distinguish it from the endogenous GHRH, allowing it to have prolonged activity in the body.
The amino acid sequence of CJC-1295 is closely related to that of GHRH but includes several key features:
Modified Amino Acid Sequence:
CJC-1295 retains the essential components of the GHRH sequence necessary for binding to GHRH receptors on pituitary cells, thereby stimulating the release of growth hormone. However, certain amino acids are substituted or modified to enhance stability and reduce susceptibility to enzymatic degradation.
Drug Affinity Complex (DAC):
One of the most significant structural features of CJC-1295 is the incorporation of a Drug Affinity Complex (DAC). This moiety allows CJC-1295 to bind covalently to albumin, a protein abundant in the bloodstream. This binding significantly extends the peptide’s half-life by preventing rapid clearance from the body, allowing for sustained GH release over several days.
Peptide Cyclization:
The structure of CJC-1295 may also involve cyclization, a common technique used in peptide chemistry to enhance stability and receptor affinity. Cyclization creates a more rigid structure that is less prone to degradation and more likely to maintain its bioactive conformation.
These structural enhancements make CJC-1295 a potent and long-acting GHRH analog, capable of inducing more sustained GH secretion compared to native GHRH or other shorter-acting analogs.
Cryo-electron microscopy (cryo-EM) has been a valuable tool in understanding the structural interactions of CJC-1295 with its target receptor, the GHRH receptor on pituitary somatotrophs. The high-resolution imaging capabilities of cryo-EM allow researchers to visualize the peptide-receptor complex at near-atomic detail, providing insights into the mechanisms that underpin CJC-1295’s prolonged activity.
Cryo-EM studies of CJC-1295 have elucidated several critical aspects of its function:
Receptor Binding Dynamics:
Cryo-EM images reveal how CJC-1295 interacts with the GHRH receptor, mimicking the natural binding of GHRH while also benefiting from structural modifications that enhance receptor engagement. These studies show how the modified amino acid sequence of CJC-1295 enables it to maintain a stable interaction with the receptor, promoting sustained activation and prolonged GH release.
Interaction with the DAC Moiety:
The cryo-EM structures highlight the role of the Drug Affinity Complex (DAC) in CJC-1295’s extended half-life. The DAC allows the peptide to bind to albumin in the bloodstream, which stabilizes the peptide and prevents rapid degradation. This interaction ensures that CJC-1295 remains active in the circulation for an extended period, continuously stimulating the release of GH.
Conformational Stability:
The structural rigidity conferred by possible cyclization in CJC-1295 is also evident in cryo-EM studies. This rigidity helps the peptide maintain its bioactive conformation, ensuring that it remains effective in binding to the GHRH receptor over time, even in the presence of proteolytic enzymes.
Through cryo-EM, researchers have been able to confirm the structural features that make CJC-1295 an effective and long-lasting GHRH analog. These detailed images provide a deeper understanding of how the peptide’s modifications enhance its therapeutic profile, supporting its use in research and potential therapeutic applications where sustained GH release is desired.
CJC-1295 operates by binding to GHRH receptors in the pituitary gland, which stimulates the release of growth hormone. What sets CJC-1295 apart from other GHRH analogs is its ability to bind to serum albumin, a protein in the bloodstream that prolongs the peptide’s half-life. This extended half-life allows CJC-1295 to remain active in the body for an extended period, often up to one to two weeks after a single administration.
The sustained presence of CJC-1295 leads to prolonged GH secretion, a key factor in promoting muscle growth and recovery. Growth hormone plays a critical role in stimulating the production of insulin-like growth factor 1 (IGF-1), a hormone that mediates many of GH’s anabolic effects. IGF-1 facilitates muscle protein synthesis, enhances the proliferation of satellite cells (precursors to muscle cells), and promotes the repair and growth of muscle tissues. By maintaining elevated levels of GH and, consequently, IGF-1, CJC-1295 supports continuous anabolic activity within muscle tissues, making it a valuable tool for research focused on muscle hypertrophy and recovery.
Numerous studies have explored the effects of CJC-1295 on muscle growth and anabolic processes, providing valuable insights into its potential applications in various research contexts. These studies have consistently demonstrated that CJC-1295 can significantly enhance muscle development, particularly when combined with other anabolic stimuli such as resistance training or other growth-promoting peptides.
The prolonged elevation of GH and IGF-1 levels induced by CJC-1295 suggests that it can provide long-term anabolic support, making it an attractive option for studies focused on muscle recovery and maintenance. This extended support is particularly relevant in research settings where continuous anabolic activity is desired, such as in studies exploring muscle regeneration after injury or in the context of chronic conditions that affect muscle mass and strength.
To fully appreciate the unique properties of CJC-1295, it is helpful to compare it with other related peptides, such as Ipamorelin, Tesamorelin, and GHRP-6, all of which are known for their roles in muscle growth and anabolic support.
Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that, like CJC-1295, promotes the release of GH. However, Ipamorelin’s mechanism of action differs in that it primarily acts on the ghrelin receptor (GHSR) rather than GHRH receptors. Ipamorelin is known for its high specificity, stimulating GH release with minimal impact on other hormones such as cortisol or prolactin. In contrast, CJC-1295’s prolonged action through GHRH receptors offers a sustained release of GH, making it more suitable for studies that require extended anabolic support.
Tesamorelin is another GHRH analog, designed specifically to increase GH levels and IGF-1 production. While both Tesamorelin and CJC-1295 stimulate GH release, CJC-1295’s ability to bind to serum albumin significantly extends its half-life, resulting in more prolonged effects. This extended duration makes CJC-1295 particularly advantageous in research contexts where a sustained anabolic response is required, such as in studies focused on muscle hypertrophy and recovery over longer periods.
GHRP-6 is a growth hormone-releasing peptide that, like Ipamorelin, acts on the ghrelin receptor to stimulate GH release. GHRP-6 is known for its potent GH-releasing effects but also stimulates the release of other hormones, including cortisol and prolactin. This broader hormonal impact can complicate its use in research focused solely on muscle growth. In contrast, CJC-1295’s targeted action on GHRH receptors, combined with its prolonged half-life, offers a more focused approach to studying muscle development and recovery.
CJC-1295’s unique properties and demonstrated efficacy in promoting muscle growth make it a promising candidate for ongoing and future research. Several areas of interest include:
Given its ability to sustain elevated GH and IGF-1 levels, CJC-1295 is ideally suited for studies focused on muscle hypertrophy. Researchers can explore its potential in enhancing muscle mass and strength, particularly in response to resistance training or other anabolic stimuli.
CJC-1295’s prolonged anabolic support suggests potential applications in research focused on muscle recovery following injury. By promoting muscle repair and regeneration, CJC-1295 could play a key role in studies aimed at improving recovery outcomes and reducing the time needed to regain muscle function.
Chronic conditions that lead to muscle wasting or reduced muscle strength could benefit from the sustained anabolic effects of CJC-1295. Future research could explore the peptide’s potential in mitigating muscle loss and supporting muscle maintenance in these contexts.
Despite the promising findings, there are still gaps in the current literature that warrant further exploration. For example, more research is needed to fully understand the long-term effects of CJC-1295 on muscle development and recovery, as well as its potential interactions with other peptides or anabolic agents. Additionally, studies exploring the molecular mechanisms underlying CJC-1295’s effects on muscle tissue could provide deeper insights into its anabolic properties.
CJC-1295 is a synthetic peptide that functions as a growth hormone-releasing hormone (GHRH) analog. Its two main forms are CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (also known as Mod GRF 1-29). The key differences between these two forms lie in their pharmacokinetics and effects on growth hormone (GH) release patterns. Here’s a comparison:
Longer Duration of Action: DAC (Drug Affinity Complex) is a modification that extends the half-life of CJC-1295 to about one week. This means it remains active in the body for a longer period, continuously stimulating GH release.
Steady GH Release: Because of its extended half-life, CJC-1295 with DAC provides a steady, sustained release of GH, mimicking the body’s natural pulsatile release to some extent but at a prolonged and steady rate.
Less Frequent Dosing: Due to its long half-life, CJC-1295 with DAC requires less frequent dosing—typically once per week, which can be more convenient for long-term use.
Broad Application: Its prolonged effect on GH release makes it suitable for objectives that benefit from elevated GH levels over an extended period, such as anti-aging, general well-being, and improved body composition.
Shorter Duration of Action: Mod GRF 1-29 has a much shorter half-life, remaining active in the body for a few minutes up to half an hour. This leads to a more immediate but transient spike in GH levels.
Mimics Natural GH Release: The short duration of action means that Mod GRF 1-29 more closely mimics the body’s natural GH release patterns, with pulsatile spikes following each injection, which can be advantageous for certain physiological responses.
More Frequent Dosing: To maintain elevated GH levels, Mod GRF 1-29 requires multiple injections throughout the day, typically 2-3 times, which may be less convenient but allows for more controlled GH release patterns.
Specific Applications: Its short-lived effect makes Mod GRF 1-29 better suited for specific goals like enhancing muscle growth and fat loss in conjunction with training and nutrition, as the timing of GH spikes can be synchronized with workouts and meals.
The choice between CJC-1295 with DAC and CJC-1295 without DAC (Mod GRF 1-29) depends on several factors, including convenience, specific health and fitness goals, and how one wishes to manage GH levels.
While CJC-1295 with DAC offers the convenience of less frequent dosing and a steady release of GH, Mod GRF 1-29 provides more control over GH spikes, potentially offering benefits that align more closely with natural GH physiology.
CJC-1295 stands out as a powerful tool in the study of muscle growth and anabolic processes, thanks to its ability to sustain elevated levels of GH and IGF-1. The peptide’s extended half-life and targeted action on GHRH receptors make it particularly effective in promoting muscle development, supporting recovery, and enhancing overall anabolic activity. As interest in peptide-based therapies continues to grow, CJC-1295 is poised to play a significant role in future research focused on optimizing muscle health and performance.
For researchers looking to explore the potential of CJC-1295 in their studies, sourcing high-quality peptides is essential. Polaris Peptides offers research-grade CJC-1295, ensuring the purity and potency necessary for reliable and impactful research.
For those looking to source high-quality CJC-1295 for research and development, Polaris Peptides offers premium-grade CJC-1295 for sale available for purchase online. Unlock the full therapeutic potential of CJC-1295 peptides by incorporating it into your next research project or therapeutic innovation.
For researchers looking to explore the potential of CJC-1295 in their studies, sourcing high-quality peptides is essential. Polaris Peptides offers research-grade CJC-1295 online, ensuring the purity and potency necessary for reliable and impactful research.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), designed to extend the half-life of GH and promote sustained anabolic activity.
CJC-1295 binds to GHRH receptors in the pituitary gland, stimulating prolonged GH secretion, which in turn increases levels of insulin-like growth factor 1 (IGF-1), a key hormone in muscle protein synthesis and growth.
CJC-1295 offers a longer duration of action and more sustained GH release compared to peptides like Ipamorelin and GHRP-6, making it particularly effective for studies requiring prolonged anabolic support.
Polaris Peptides is a trusted supplier of research-grade CJC-1295, offering high-quality peptides that meet rigorous standards for purity and potency, ideal for muscle growth research.
CJC-1295 is particularly useful in studies focused on muscle hypertrophy, recovery from injury, and anabolic support in chronic conditions that affect muscle mass and strength.
At Polaris Peptides, we are dedicated to supporting the scientific community by supplying high-quality peptides designed exclusively for research and development endeavors of professionals. Our products are crafted for investigative purposes and are not suitable for direct human consumption or consumers, nor are they intended for clinical or therapeutic use. We uphold a strict policy to ensure our peptides are recognized distinctly from prescription medications as an entity committed to research.
Polaris Peptides is a chemical supplier. Polaris Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Polaris Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Products
Legal
Customer Service
To contact management, please email *@*************es.com
You may also call or leave us a message at (800) 273-9462. Please note during busy times (such as Black Friday) we may not be able to answer all calls. Please leave a voicemail with all necessary details or email us at our support email.
© 2025 Polaris Peptides. All Rights Reserved.
Discount Applied Successfully!
Your savings have been added to the cart.
Join our Polaris Insiders program to get rewarded for loyalty with exclusive deals, news about upcoming products, and more.
You must be 18 years old or older in order to access our website. Please verify your age.